Finerenone as a New Potent Resistant Hypertension Agent: A Review
Sanatkumar Bharamu Nyamagoud1, Agadi Hiremath Viswanatha Swamy1, Jayasheela Hiremath, Abhishek BJ1, Saurav Raj1, Megha Hegde1, Dhananjay Tikadar1, Raviteja Somashekhar Kanavi1, Rohith Javali Veeresh1
- 1Department of Pharmacy Practice, KLE College of Pharmacy (A Constituent unit of KLE Academy of Higher Education and Research, Belagavi), Vidyanagar, Hubballi. Karnataka, INDIA.
Received: 01-08-2023; Revised: 07-09-2023; Accepted: 01-10-2023.
Volume 14, Issue 1 · pp. 10–15 · PUBLISHED · DOI: 10.5530/ijpi.14.1.2
ABSTRACT
Background:The drug Finerenone, a selective the drug mineralocorticoid receptor antagonist, indicated for Chronic Kidney Disease (CKD) and Type 2 Diabetes. Recent researchers also found add on role in the management of resistant hypertension. So, this review article aims to provide an in-depth understanding of finerenone and the objective is to explore the mechanism of action, efficacy, and potential benefits of finerenone in treating (CKD) and heart failure with reduced ejection fraction (HFrEF), specifically in patients who have both type 2 diabetes (T2D) and CKD. Materials and Methods: A systematic literature search was done using IBM Micromedex, PubMed, Cochrane Library, and Scopus databases to identify relevant English-language articles published between 2000 and March 2023. Search terms included "Finerenone," "MRA," "Resistant Hypertension," "Finerenone Efficacy," and "Pharmacology of Finerenone." The selection criteria included clinical trials, randomized trials, and original articles, with references listed chronologically. Results: Finerenone's selective blockade of mineralocorticoid receptors counteracts the adverse effects of aldosterone, exhibiting anti-inflammatory and anti-fibrotic properties. Clinical trials consistently demonstrate its efficacy in reducing albuminuria, slowing CKD progression, and improving cardiovascular outcomes in patients with T2D and CKD. The recent approval of finerenone by the FDA for reducing the risk of death and abnormal cardiovascular events in adults with CKD and T2D with HFrEF highlights its therapeutic potential. Conclusion: Finerenone represents a pharmacological breakthrough in the management of resistant hypertension, offering a comprehensive therapeutic approach for patients with CKD and T2D. Its selective mineralocorticoid receptor antagonism, combined with anti-inflammatory and anti-fibrotic effects, shows promise in improving long-term renal and cardiovascular health. However, further research is needed to fully understand its long-term benefits, safety profile, and optimal utilization in the management of resistant hypertension. Finerenone's emergence provides new possibilities for patient care and signifies a significant advancement in the treatment of CKD and T2D, with the potential to enhance patient outcomes and quality of life.
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Nyamagoud, S. B., Swamy, A. H. V., BJ, J. H. A., Raj, S., Hegde, M., Tikadar, D., Kanavi, R. S., & Veeresh, R. J. (). Finerenone as a New Potent Resistant Hypertension Agent: A Review. International Journal of Pharmaceutical Investigation, 14(1), 10–15. https://doi.org/10.5530/ijpi.14.1.2